Press Releases Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Market Closed - Nasdaq Other stock markets 21:30:00 10/05/2024 BST			5-day change	1st Jan Change
0.9401 ^USD	+2.34%		+16.97%	+5.75%

05-08	Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-05	Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	05-08	AQ
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights	04-04	AQ
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	04-04	AQ
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference	02-05	AQ
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction	12-18	AQ
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights	11-13	AQ
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	22/09/23	AQ
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	04/08/23	AQ
Achilles Therapeutics : Corporate Presentation – August 2023	04/08/23	PU
Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	29/06/23	PU
IO Summit EU 2023 - Personalised Neoantigen Therapies: State of the Art Neoantigen Immunogenicity Prediction	22/06/23	PU
Achilles Therapeutics : SAE Cell and Gene Therapy 2023 - Targeting Clonal Neoantigens in Cancer	22/06/23	PU
Achilles Therapeutics to Present at Upcoming Conferences	12/06/23	AQ
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights	10/05/23	AQ
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens	10/05/23	AQ
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	25/04/23	AQ
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status	25/04/23	AQ
Achilles Therapeutics : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - Form 6-K	24/04/23	PU
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit	17/04/23	AQ
Achilles Therapeutics : Corporate Presentation – March 2023	07/03/23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Press Releases

Filters